FTC suit over PBMs’ insulin pricing is delayed in part by Trump firings

Taking stock of the drug industry, from the lab to the medicine chest

April 2, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Graeme Jennings/Washington Examiner via AP STAT+ | FTC suit over PBMs' insulin pricing is delayed in part by Trump firings The delay comes because because the agency does not have enough commissioners to hear the case. It is a "gift to the PBMs," says former chair Lina Khan. By Ed Silverman STAT+ | Trump administration begins mass cuts of federal health policy researchers ASPE and AHRQ are losing key research staff as part of the HHS cuts Tuesday. Current and former employees worry vital data-driven research will suffer. By Bob Herman and Tara Bannow STAT+ | FDA Commissioner Marty Makary gets off to a bruising start as agency is wracked by layoffs Sweeping FDA cuts give Makary, RFK Jr. chance to reshape FDA. Yet remaining workers face daunting task of doing the same work with fewer people. By Lizzy Lawrence and Sarah Todd Adobe STAT+ | Vida Ventures brings in new leaders after co-founders' departure The firm announced Wednesday that it has hired longtime J.P. Morgan portfolio manager Matt Cohen and former MPM BioImpact partner Brian Goodman. By Allison DeAngelis

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser